25978-74-9

Basic information

• Product Name: METHYL 3-CYANO-4-METHOXYBENZOATE
• Synonyms: METHYL 3-CYANO-4-METHOXYBENZOATE;3-Cyano-4-methoxybenzoic acid methyl ester
• CAS NO: 25978-74-9
• Molecular Formula: C₁₀H₉NO₃
• Molecular Weight: 191.18
• EINECS: -0
• Product Categories: Aromatic Esters
• Mol File: 25978-74-9.mol
• Article Data: 8

Chemical Properties

• Melting Point: 124 °C
• Boiling Point: 339.7 °C at 760 mmHg
• Flash Point: 148.2 °C
• Appearance: light brown solid
• Density: 1.2 g/cm³
• Vapor Pressure: 9.03E-05mmHg at 25°C
• Refractive Index: 1.527
• Storage Temp.: Sealed in dry,Room Temperature
• BRN: 2374769
• CAS DataBase Reference: METHYL 3-CYANO-4-METHOXYBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 3-CYANO-4-METHOXYBENZOATE(25978-74-9)
• EPA Substance Registry System: METHYL 3-CYANO-4-METHOXYBENZOATE(25978-74-9)

Safety Data

• Hazard Codes: Xn:Harmful
• Statements: 20/21/22-36/37/38
• Safety Statements: 26-36/37/39
• RIDADR: 3439
• HazardClass: 6.1
• PackingGroup: III
• Hazardous Substances Data: 25978-74-9(Hazardous Substances Data)

Usage

Uses

Methyl 3-Cyano-4-methoxybenzoate is a useful research chemical.

InChI:InChI=1/C10H9NO3/c1-13-9-4-3-7(10(12)14-2)5-8(9)6-11/h3-5H,1-2H3

Upstream product

• 2150-38-1 methyl 3,4-dimethoxybenzoate 
• 75-86-5 2-hydroxy-2-methylpropanenitrile 
• 121-98-2 methyl 4-methoxybenzoate 
• 35450-37-4 methyl 3-bromo-4-methoxybenzoate 
• 29415-97-2 methyl 3-bromo-4-hydroxybenzoate 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 77-78-1 dimethyl sulfate 
• 156001-68-2 methyl 3-cyano-4-hydroxybenzoate 
• 74-88-4 methyl iodide 

Downstream Products

• 70829-28-6 3-cyano-4-hydroxybenzoic acid 
• 121-98-2 methyl 4-methoxybenzoate 
• 117738-82-6 4-methoxy-3-cyanobenzoic acid 
• 1167416-41-2 1,1-dimethylethyl 7-(5-(3-cyano-4-(1-methylethyloxy)phenyl)-1,2,4-oxadiazol-3-yl)-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate 
• 1285572-76-0 3-(3-cyano-4-hydroxy-5-methylsulfanylbenzoyl)-1,1-dioxo-1,2-dihydro-3H-1,3-benzothiazole 
• 1285573-25-2 3-(3-cyano-5-ethylsulfanyl-4-hydroxybenzoyl)-1,1-dioxo-2,3-dihydro-1,3-benzothiazole 
• 1285574-82-4 3-(3-cyano-4-hydroxy-5-iodobenzoyl)-1,1-dioxo-2,3-dihydro-1,3-benzothiazole 
• 1285574-83-5 3-(3-cyano-4-methoxy-5-methylsulfanylbenzoyl)-1,1-dioxo-2,3-dihydro-1,3-benzothiazole 
• 1285572-78-2 3-(3-cyano-4-hydroxy-5-methylsulfonylbenzoyl)-1,1-dioxo-2,3-dihydro-1,3-benzothiazole 
• 1285574-85-7 3-(3-cyano-4-methoxy-5-methylsulfonylbenzoyl)-1,1-dioxo-2,3-dihydro-1,3-benzothiazole 
• 1285575-97-4 3-(3-cyano-4-methoxybenzoyl)-2,3-dihydro-1,3-benzothiazole 
• 1285576-00-2 3-(3-cyano-4-methoxybenzoyl)-1,1-dioxo-2,3-dihydro-1,3-benzothiazole 
• 1285576-01-3 3-(3-cyano-4-hydroxybenzoyl)-1,1-dioxo-2,3-dihydro-1,3-benzothiazole 
• 1285573-28-5 3-(3-cyano-4-hydroxy-5-isopropylsulfanylbenzoyl)-1,1-dioxo-2,3-dihydro-1,3-benzothiazole 

Relevant articles and documents

Arene Cyanation via Cation-Radical Accelerated-Nucleophilic Aromatic Substitution

Herein we describe a cation radical-accelerated-nucleophilic aromatic substitution (CRA-SNAr) of alkoxy arenes utilizing a highly oxidizing acridinium photoredox catalyst and acetone cyanohydrin, an inexpensive and commercially available cyanide source. This cyanation is selective for carbon-oxygen (C-O) bond functionalization and is applicable to a range of methoxyarenes and dimethoxyarenes. Furthermore, computational studies provide a model for predicting regioselectivity and chemoselectivity in competitive C-H and C-O cyanation of methoxyarene cation radicals.

HETEROCYCLIC-IMIDAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF

The present invention relates to a heterocyclic-imidazole derivative, a preparation method therefor, and a medical use thereof, and particularly to a new heterocyclic-imidazole derivative of general Formula (I), a preparation method therefor, a pharmaceutical composition comprising the same, and use thereof as a therapeutic agent, particularly as a poly(ADP-ribose)polymerase (PARP) inhibitor.

Heterocycle and imidazole compounds, pharmaceutical composition comprising heterocycle and imidazole derivatives as well as preparation method and application of heterocycle and imidazole compounds

The invention relates to heterocycle and imidazole derivatives as well as a preparation method and a pharmaceutical application of heterocycle and imidazole derivatives, in particular to novel heterocycle and imidazole derivatives as shown in the general formula (I), a preparation method of the heterocycle and imidazole derivatives, pharmaceutical composition comprising the heterocycle and imidazole derivatives as well as an application of the heterocycle and imidazole derivatives as a therapeutic agent and particularly as a PARP (poly (ADP-ribose) polymerase) inhibitor.